Pharmaceutical composition containing poly(bile) acid (PBA) polymers for oral delivery of agent(s) show enhanced uptake by the pancreas, liver, and colon. These nanoparticles show significant retention in the pancreas and colon and are therefore useful for selective delivery. The examples demonstrate efficacy of oral administration of insulin to treat diabetes, and oral induction of tolerance by administration of insulin or ovalbumin in combination with rapamycin. Diabetic animals treated with the insulin or insulin with rapamycin showed normalization of blood glucose levels.

The present invention relates to a particle composition for use as a contrasting agent in medical imaging such as Magnetic Resonance Imaging (MRI), the particle composition comprising: a metal containing compound comprises at least one metal complexed with at least one metal chelating agent; wherein the metal chelating agent is adapted to bind to one or more protein molecules to thereby allow or enhance visibility of the protein molecules under the medical imaging. The present invention further relates to a diagnostic agent for use in magnetic resonance imaging (MRI) comprising the above described particle composition; and a method of preparing thereof.

The present invention relates to a composition for use as a contrast agent in medical imaging. The composition comprises a metal ion containing compound comprises at least one metal ion adapted to bind with one or more metal ion chelating agents; wherein said one or more metal ion chelating agents comprise at least one first chelating agent adapted to target a region of interest being imaged, and at least one second chelating agent having at least one functional group adapted to dissociate in an aqueous medium to thereby allow or enhance contrast of the region of interest under the medical imaging. The present invention further relates to a diagnostic agent for use in amyloid (A) protein detection under magnetic resonance imaging (MRI) comprising the above described composition; and a method of preparing thereof.

An amyloidogenic peptide biospecific agent comprises a nanoparticle which is visible under near infrared (NIR) and/or using Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT). The biospecific agent further comprises at least one antibody or antigen binding fragment thereof, which is immunospecific for a transferrin receptor and an amyloidogenic peptide.

A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material.

The present invention relates to paramagnetic solid lipid nanoparticles (pSLNs) comprising an amphiphilic paramagnetic metal chelating moiety selected from: a diazepine derivative of Formula I and a tetraazocyclododecane derivative of Formula (II): being said chelating moiety complexed to a paramagnetic metal ion selected from the group consisting of: Gd(III), Mn(II), Cr(III), Cu(II), Fe(III), Pr(III), Nd(III), Sm(III), Tb(III), Yb(III), Dy(III), Ho(III) and Er(III), or salts thereof. The invention further relates to the process for preparation of said solid lipid nanoparticles comprising amphiphilic complexes of paramagnetic metals (pSLNs) and to the use of pSLNs as MRI contrast agents in the diagnostic field.

The present invention relates to an imaging diagnostic method, comprising a contrast agent including a contrast enhancer in a magnetic resonance imaging (MRI) assisted diagnosis of carcinoma diseases or carcinomas, in particular of hepatocellular carcinoma (HCC). The contrast agent is preferably a gadolinium compound, preferably Gd-DTPA including iRGD as a contrast enhancer, for the improved imaging of carcinomas, in particular HCC, in MRI. The invention furthermore relates to a method for the risk stratification of patients and subjects using the aforementioned diagnosis.

The present invention relates to an imaging diagnostic method, comprising a contrast agent including a contrast enhancer in a magnetic resonance imaging (MRI) assisted diagnosis of carcinoma diseases or carcinomas, in particular of hepatocellular carcinoma (HCC). The contrast agent is preferably a gadolinium compound, preferably Gd-DTPA including iRGD as a contrast enhancer, for the improved imaging of carcinomas, in particular HCC, in MRI. The invention furthermore relates to a method for the risk stratification of patients and subjects using the aforementioned diagnosis.

A composition comprises an anti-nucleolin agent conjugated to nanoparticles, and optionally containing gadolinium. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. The composition enhances the effectiveness of radiation therapy, enhancing contrast in X-ray imaging techniques, and when gadolinium is present, provide cancer selective MRI contrast agents.